CNTA vs ARQT vs JPM

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Centessa Pharmaceuticals plc (CNTA) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, JPMorgan Chase & Co.

is actually cheaper at 14. 1x.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +110. 0%, compared to -13. 3% for Arcutis Biotherapeutics, Inc. (ARQT). Over 10 years, the gap is even starker: JPM returned +465. 8% versus ARQT's +11. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), JPMorgan Chase & Co.

(JPM) is the lower-risk stock at 0. 94β versus Arcutis Biotherapeutics, Inc. 's 1. 45β — meaning ARQT is approximately 53% more volatile than JPM relative to the S&P 500. On balance sheet safety, Centessa Pharmaceuticals plc (CNTA) carries a lower debt/equity ratio of 1% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to 1. 5% for JPMorgan Chase & Co.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus -1316. 9% for Centessa Pharmaceuticals plc — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus -1384. 6% for CNTA. At the gross margin level — before operating expenses — CNTA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, JPMorgan Chase & Co.

(JPM) trades at 14. 1x forward P/E versus 122. 5x for Arcutis Biotherapeutics, Inc. — 108. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARQT: 38. 3% to $34. 00.

In this comparison, JPM (1.

9% yield) pays a dividend. CNTA, ARQT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94), 1. 9% yield, +465. 8% 10Y return). Both have compounded well over 10 years (JPM: +465. 8%, ARQT: +11. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CNTA (Healthcare) and ARQT (Healthcare) and JPM (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CNTA is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; JPM is a large-cap deep-value stock. JPM pays a dividend while CNTA, ARQT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.